Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) CEO Thomas J. Schuetz purchased 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Tuesday, January 24th. The stock was acquired at an average cost of $4.19 per share, with a total value of $83,800.00. Following the acquisition, the chief executive officer now directly owns 5,451,873 shares in the company, valued at approximately $22,843,347.87. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Compass Therapeutics Stock Performance
Shares of CMPX stock traded up $0.60 during trading hours on Tuesday, reaching $4.41. The company had a trading volume of 358,819 shares, compared to its average volume of 351,395. The stock has a fifty day moving average of $4.70 and a 200-day moving average of $3.57. The company has a market capitalization of $556.50 million, a price-to-earnings ratio of -10.36 and a beta of 1.35. Compass Therapeutics, Inc. has a 12-month low of $1.25 and a 12-month high of $5.65.
Compass Therapeutics (NASDAQ:CMPX – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, analysts forecast that Compass Therapeutics, Inc. will post -0.39 EPS for the current year.
Wall Street Analyst Weigh In
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new position in Compass Therapeutics during the third quarter worth $55,000. Jane Street Group LLC acquired a new position in Compass Therapeutics during the third quarter worth $33,000. Vanguard Group Inc. lifted its stake in Compass Therapeutics by 58.5% during the third quarter. Vanguard Group Inc. now owns 2,380,623 shares of the company’s stock worth $5,428,000 after purchasing an additional 878,650 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Compass Therapeutics by 118.4% in the third quarter. Marshall Wace LLP now owns 51,816 shares of the company’s stock valued at $117,000 after acquiring an additional 28,089 shares in the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in shares of Compass Therapeutics in the third quarter valued at $2,509,000. 54.27% of the stock is currently owned by hedge funds and other institutional investors.
About Compass Therapeutics
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.
- Get a free copy of the StockNews.com research report on Compass Therapeutics (CMPX)
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.